Clinical Trial Search

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Total Number of Adverse Events. — 2 Adverse events

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Objective Response Rate — .85 proportion of patients

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL. — 3; 2 Participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Progression-free Survival at 2 Years — 15 Participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167

Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants

Primary: Maximum Tolerated Dose (MTD) of MEDI-551 — NA; NA mg/kg

Primary: Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications — 4; 1; 3 Participants

Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Progression Free Survival (PFS) — 71.2; 54.2 percentage of participants

Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: Percentage of Participants With Complete Response (CR) at End of Treatment Period — 31; 25 percentage of participants

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1] — 0; 0; 3; 1 participants

Primary: Optimal Biologic Dose of MEDI-551 for Part A — 12 mg/Kg

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Progression-free Survival — 72 Percent